At Pelvalon, we believe in finding simple solutions to difficult problems. We aim to change the lives of women who suffer from loss of bowel control. We are dedicated to helping women achieve confidence, control, and a better quality of life. Founded in 2010, Pelvalon’s innovative new technology originated from Stanford University’s Biodesign program, a collaboration between the schools of Medicine and Engineering. The Biodesign program encourages the development of user-driven solutions to unmet medical needs, and we are proud to carry on the tradition of biomedical innovation. Pelvalon is privately held, and our investors include Norwich Ventures, a specialized venture capital firm focused on medical technology.